Overview of lethal human coronaviruses

Coronavirus infections of multiple origins have spread to date worldwide, causing severe respiratory diseases. Seven coronaviruses that infect humans have been identified: HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2. Among them, SARS-CoV and MERS-CoV caused outbreaks in 2002 and 2012, respectively. SARS-CoV-2 (COVID-19) is the most recently discovered. It has created a severe worldwide outbreak beginning in late 2019, leading to date to over 4 million cases globally. Viruses are genetically simple, yet highly diverse. However, the recent outbreaks of SARS-CoV and MERS-CoV, and the ongoing outbreak of SARS-CoV-2, indicate that there remains a long way to go to identify and develop specific therapeutic treatments. Only after gaining a better understanding of their pathogenic mechanisms can we minimize viral pandemics. This paper mainly focuses on SARS-CoV, MERS-CoV, and SARS-CoV-2. Here, recent studies are summarized and reviewed, with a focus on virus–host interactions, vaccine-based and drug-targeted therapies, and the development of new approaches for clinical diagnosis and treatment.

[1]  Shibo Jiang,et al.  Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design , 2014, Vaccine.

[2]  Lin-Fa Wang,et al.  Review of Bats and SARS , 2006, Emerging infectious diseases.

[3]  F. Weber,et al.  Middle East Respiratory Syndrome Coronavirus Accessory Protein 4a Is a Type I Interferon Antagonist , 2013, Journal of Virology.

[4]  Sangdun Choi,et al.  Structural insights into the Middle East respiratory syndrome coronavirus 4a protein and its dsRNA binding mechanism , 2017, Scientific Reports.

[5]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[6]  Qiang Zhou,et al.  Structure of dimeric full-length human ACE2 in complex with B0AT1 , 2020, bioRxiv.

[7]  Rajaa Al-Raddadi,et al.  Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome , 2017, American journal of respiratory and critical care medicine.

[8]  J. Sung,et al.  Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients , 2004, Clinical Microbiology and Infection.

[9]  Tae-Jin Kang,et al.  Expression of B subunit of E. coli heat-labile enterotoxin in the progenies of transgenic tobacco bred by crossing nuclear- and chloroplast-transgenic lines. , 2019, Protein expression and purification.

[10]  Cheng-wei Lu,et al.  2019-nCoV transmission through the ocular surface must not be ignored , 2020, The Lancet.

[11]  Edith Jasny,et al.  New Vaccine Technologies to Combat Outbreak Situations , 2018, Front. Immunol..

[12]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[13]  Jiahua He,et al.  Molecular Mechanism of Evolution and Human Infection with SARS-CoV-2 , 2020, Viruses.

[14]  K. Holmes,et al.  SARS-associated coronavirus. , 2003, The New England journal of medicine.

[15]  Qingling Zhang,et al.  Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.

[16]  F. Lai,et al.  Acute renal impairment in coronavirus-associated severe acute respiratory syndrome , 2005, Kidney International.

[17]  R. Favory,et al.  Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases , 2014, Journal of Clinical Virology.

[18]  J. Peiris,et al.  Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003 , 2003, The Lancet.

[19]  J. Yu,et al.  DNA Vaccine of SARS-Cov S Gene Induces Antibody Response in Mice , 2004, Acta biochimica et biophysica Sinica.

[20]  Chuan Qin,et al.  Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways , 2015, The Journal of infectious diseases.

[21]  P. Marik,et al.  A Descriptive Study , 2015 .

[22]  N. Houhou-Fidouh,et al.  Focus on Middle East respiratory syndrome coronavirus (MERS-CoV) , 2019, Médecine et Maladies Infectieuses.

[23]  Shibo Jiang,et al.  Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine , 2004, Biochemical and Biophysical Research Communications.

[24]  R. Korstanje,et al.  The emerging role of ACE2 in physiology and disease† , 2007, The Journal of pathology.

[25]  Z. Memish,et al.  Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus , 2017, Science Advances.

[26]  D. Swerdlow,et al.  Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014 , 2016, The American Journal of Pathology.

[27]  Yi Xiao,et al.  Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV) , 2020, bioRxiv.

[28]  B. Fielding,et al.  MERS-CoV: Understanding the Latest Human Coronavirus Threat , 2018, Viruses.

[29]  P. Jahrling,et al.  One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus , 2016, Journal of Virology.

[30]  C. Hsiao,et al.  The SARS coronavirus nucleocapsid protein – Forms and functions , 2014, Antiviral Research.

[31]  Xin Li,et al.  Global Epidemiology of Bat Coronaviruses , 2019, Viruses.

[32]  Bo Zhang,et al.  Multiple organ infection and the pathogenesis of SARS , 2005, The Journal of experimental medicine.

[33]  Shibo Jiang,et al.  Prospects for a MERS-CoV spike vaccine , 2018, Expert review of vaccines.

[34]  Lanjuan Li,et al.  Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins , 2019, Engineering.

[35]  G. Ha,et al.  Development and Validation of a Rapid Immunochromatographic Assay for Detection of Middle East Respiratory Syndrome Coronavirus Antigen in Dromedary Camels , 2015, Journal of Clinical Microbiology.

[36]  Z. Memish,et al.  The Middle East Respiratory Syndrome (MERS) , 2019, Infectious Disease Clinics of North America.

[37]  Yonghong Xiao,et al.  Host and infectivity prediction of Wuhan 2019 novel coronavirus using deep learning algorithm , 2020, bioRxiv.

[38]  D. Weiner,et al.  Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial , 2019, The Lancet Infectious Diseases.

[39]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[40]  Y. Kitade,et al.  Association of host tropism of Middle East syndrome coronavirus with the amino acid structure of host cell receptor dipeptidyl peptidase 4. , 2014, Acta virologica.

[41]  G. Gao,et al.  MERS-CoV spike protein: Targets for vaccines and therapeutics , 2016, Antiviral Research.

[42]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[43]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[44]  L. M. Mansky,et al.  A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses , 2011, Journal of Virology.

[45]  Kunqian Yu,et al.  Theoretical Study of the anti-NCP Molecular Mechanism of Traditional Chinese Medicine Lianhua-Qingwen Formula (LQF) , 2020 .

[46]  K. Moon,et al.  A Case Report of a Middle East Respiratory Syndrome Survivor with Kidney Biopsy Results , 2016, Journal of Korean medical science.

[47]  G. Gao,et al.  Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses , 2016, Trends in Microbiology.

[48]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[49]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[50]  Ali Al-Hazmi,et al.  Challenges presented by MERS corona virus, and SARS corona virus to global health , 2016, Saudi Journal of Biological Sciences.

[51]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[52]  M. McNutt,et al.  Pathogenetic mechanisms of severe acute respiratory syndrome , 2007, Virus Research.

[53]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[54]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[55]  Ching-lung Lai,et al.  SARS‐associated viral hepatitis caused by a novel coronavirus: Report of three cases , 2004, Hepatology.

[56]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[57]  Krishna Shankara Narayanan,et al.  The Endonucleolytic RNA Cleavage Function of nsp1 of Middle East Respiratory Syndrome Coronavirus Promotes the Production of Infectious Virus Particles in Specific Human Cell Lines , 2018, Journal of Virology.

[58]  Daphne A. Cooper,et al.  Ribonuclease L and metal-ion–independent endoribonuclease cleavage sites in host and viral RNAs , 2014, Nucleic acids research.

[59]  Yang Yang,et al.  The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. , 2014, Viral immunology.

[60]  Wenjun Ma,et al.  Transmission dynamics of 2019 novel coronavirus (2019-nCoV) , 2020, bioRxiv.

[61]  Zhihang Peng,et al.  Modeling the Epidemic Trend of the 2019 Novel Coronavirus Outbreak in China , 2020, bioRxiv.

[62]  M. Ulaşlı,et al.  Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle , 2019, Journal of Virology.

[63]  F. Taguchi,et al.  Studies of Severe Acute Respiratory Syndrome Coronavirus Pathology in Human Cases and Animal Models , 2010, Veterinary pathology.

[64]  Yang Yang,et al.  The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists , 2013, Protein & Cell.

[65]  Lu Lu,et al.  Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor , 2014, Nature Communications.

[66]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[67]  Zhaohui Zheng,et al.  SARS-CoV-2 invades host cells via a novel route: CD147-spike protein , 2020, bioRxiv.

[68]  Lisa E. Gralinski,et al.  Middle East Respiratory Syndrome Coronavirus Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis , 2017, mSphere.

[69]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[70]  Xin Li,et al.  The clinical pathology of severe acute respiratory syndrome (SARS): a report from China , 2003, The Journal of pathology.

[71]  Ping Zhu,et al.  Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial , 2020, medRxiv.

[72]  C. Althaus,et al.  Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[73]  M. Song,et al.  Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein , 2020, Virus Research.

[74]  J. Dennis,et al.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.

[75]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[76]  A. Haneya,et al.  Impact of Acute Kidney Injury on Outcome in Patients With Severe Acute Respiratory Failure Receiving Extracorporeal Membrane Oxygenation* , 2015, Critical care medicine.

[77]  J. Laffey,et al.  Cell therapy in acute respiratory distress syndrome. , 2018, Journal of thoracic disease.

[78]  D. Dimitrov,et al.  Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies , 2007, Proceedings of the National Academy of Sciences.

[79]  A. Debnath,et al.  Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.

[80]  Yue Chen,et al.  Evolution and variation of 2019-novel coronavirus , 2020, bioRxiv.

[81]  Chuan Qin,et al.  From SARS to MERS, Thrusting Coronaviruses into the Spotlight , 2019, Viruses.

[82]  P. Vollmar,et al.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.

[83]  T. Rice,et al.  A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension , 2018, European Respiratory Journal.

[84]  Susan I Gerber,et al.  2014 MERS-CoV outbreak in Jeddah--a link to health care facilities. , 2015, The New England journal of medicine.

[85]  Christian Drosten,et al.  Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS , 2013, Antiviral Research.

[86]  Zhiwei Chen,et al.  Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques , 2015, Mucosal Immunology.

[87]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[88]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[89]  E. Koonin,et al.  Origins and Evolution of the Global RNA Virome , 2018, mBio.

[90]  H. Balkhy,et al.  Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review , 2017, Journal of Infection and Public Health.

[91]  S. Kaufmann,et al.  Challenges and responses in human vaccine development. , 2014, Current opinion in immunology.

[92]  S. Weiss,et al.  Murine Coronavirus Mouse Hepatitis Virus Is Recognized by MDA5 and Induces Type I Interferon in Brain Macrophages/Microglia , 2008, Journal of Virology.

[93]  C. Chou,et al.  Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes , 2017, Antiviral Research.

[94]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[95]  Yinying Lu,et al.  Two Things about COVID-19 Might Need Attention , 2020 .

[96]  B. Bosch,et al.  Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody , 2013, Journal of Virology.

[97]  Lu Lu,et al.  Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein , 2014, Virus Research.

[98]  S. Al-Benna Angiotensin-converting enzyme 2 gene expression in human male urological tissues: implications for pathogenesis and virus transmission pathways , 2021, African Journal of Urology.

[99]  K. Yuen,et al.  Development of a standard treatment protocol for severe acute respiratory syndrome , 2003, The Lancet.

[100]  Z. Memish,et al.  MERS-CoV as an emerging respiratory illness: A review of prevention methods , 2019, Travel Medicine and Infectious Disease.

[101]  Xiu-Jie Wang,et al.  Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines , 2020, Journal of Genetics and Genomics.

[102]  E. Holmes,et al.  Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China , 2020, bioRxiv.

[103]  D. Hamer Faculty Opinions recommendation of Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[104]  R. C. Macridis A review , 1963 .

[105]  A. Debnath,et al.  Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development , 2013, Journal of Virology.

[106]  Z. Hong,et al.  Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study , 2020, Journal of Infection.

[107]  D. Dimitrov,et al.  Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies , 2014, Journal of Virology.

[108]  K. Yuen,et al.  Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein , 2014, Science Translational Medicine.

[109]  P. Niu,et al.  Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein , 2019, Nature Communications.

[110]  J. Penninger,et al.  Angiotensin-converting enzyme 2 in lung diseases , 2006, Current Opinion in Pharmacology.

[111]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[112]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[113]  Shibo Jiang,et al.  Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors , 2018, Journal of medicinal chemistry.

[114]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[115]  C. Lam,et al.  Severe acute respiratory syndrome: clinical and laboratory manifestations. , 2004, The Clinical biochemist. Reviews.

[116]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[117]  O. Jahn,et al.  TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein , 2013, Journal of Virology.

[118]  A. Gambotto,et al.  Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice , 2014, Vaccine.

[119]  C. Broder,et al.  Identification of a Broad-Spectrum Antiviral Small Molecule against Severe Acute Respiratory Syndrome Coronavirus and Ebola, Hendra, and Nipah Viruses by Using a Novel High-Throughput Screening Assay , 2014, Journal of Virology.

[120]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[121]  J. Mascola,et al.  A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial , 2008, Vaccine.

[122]  Shibo Jiang,et al.  De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery , 2018, Journal of medicinal chemistry.

[123]  J. Segalés,et al.  An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels , 2016, Science.

[124]  Krystal L. Matthews,et al.  The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. , 2014, The Journal of general virology.

[125]  Jie Hao,et al.  Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection , 2020, Frontiers of Medicine.

[126]  Wenhui Li,et al.  Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[127]  Xiang Li,et al.  On the origin and continuing evolution of SARS-CoV-2 , 2020, National science review.

[128]  Sek-Man Wong,et al.  Yeast expression and characterization of SARS-CoV N protein , 2005, Journal of Virological Methods.

[129]  B. Bosch,et al.  Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.

[130]  Z. Memish,et al.  Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[131]  S. Meo,et al.  Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. , 2018, European review for medical and pharmacological sciences.

[132]  R. Silverman,et al.  Dimeric Structure of Pseudokinase RNase L Bound to 2-5A Reveals a Basis for Interferon-Induced Antiviral Activity , 2014, Molecular Cell.

[133]  K. Erles,et al.  Detection of a group 2 coronavirus in dogs with canine infectious respiratory disease , 2003, Virology.

[134]  Susanna K. P. Lau,et al.  Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease , 2015, Clinical Microbiology Reviews.

[135]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[136]  Su-Jin Park,et al.  Environmental Contamination and Viral Shedding in MERS Patients During MERS-CoV Outbreak in South Korea , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[137]  P. Britton,et al.  Activation of the Chicken Type I Interferon Response by Infectious Bronchitis Coronavirus , 2014, Journal of Virology.

[138]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[139]  R. Silverman Viral Encounters with 2′,5′-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response , 2007, Journal of Virology.

[140]  G. Whittaker,et al.  Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses , 2020, bioRxiv.

[141]  Zhigang Tian,et al.  Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus , 2020, bioRxiv.

[142]  Caution: The clinical characteristics of COVID-19 patients at admission are changing , 2020, medRxiv.

[143]  J. Bogdanowicz,et al.  REPORT OF THREE CASES. , 1963, American journal of diseases of children.

[144]  Shu-Chun Cheng,et al.  Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus , 2014, Antiviral Research.

[145]  Huji Xu,et al.  The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes , 2020, bioRxiv.

[146]  Lu Lu,et al.  Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein , 2020, Cellular & Molecular Immunology.

[147]  J. Al-Tawfiq,et al.  A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) , 2019, Travel Medicine and Infectious Disease.

[148]  Yi Shi,et al.  Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.

[149]  M. V. Van Kerkhove,et al.  MERS: Progress on the global response, remaining challenges and the way forward , 2018, Antiviral Research.

[150]  Willis J. Tompkins,et al.  Report from China , 1984, IEEE Engineering in Medicine and Biology Magazine.

[151]  R. Silverman,et al.  Homologous 2′,5′-phosphodiesterases from disparate RNA viruses antagonize antiviral innate immunity , 2013, Proceedings of the National Academy of Sciences.

[152]  Md. Siddikur Rahman,et al.  The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? , 2020, International journal of epidemiology.

[153]  E. Koonin,et al.  Classify viruses — the gain is worth the pain , 2019, Nature.

[154]  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, Emerging microbes & infections.

[155]  Tao Liu,et al.  Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China , 2020, medRxiv.

[156]  R. Lu,et al.  Mutations, Recombination and Insertion in the Evolution of 2019-nCoV , 2020, bioRxiv.

[157]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[158]  S. Rajagopalan,et al.  An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. , 2013, Atherosclerosis.

[159]  W. Zuo,et al.  Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov , 2020, bioRxiv.

[160]  Julie Dyall,et al.  Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.

[161]  L. Qiu,et al.  A preliminary study , 2018, Medicine.

[162]  Rong Zhao,et al.  Crystal structure of Middle East respiratory syndrome coronavirus helicase , 2017, PLoS pathogens.

[163]  Shifeng Li,et al.  Interaction of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline with the angiotensin‐converting enzyme 2–angiotensin‐(1–7)–Mas axis attenuates pulmonary fibrosis in silicotic rats , 2019, Experimental Physiology.

[164]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[165]  D. Hui,et al.  Severe acute respiratory syndrome and Toronto , 2003, Journal of epidemiology and community health.

[166]  R. Baric,et al.  Crystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.

[167]  Z. Deng,et al.  Nanopore Targeted Sequencing for the Accurate and Comprehensive Detection of SARS‐CoV‐2 and Other Respiratory Viruses , 2020, medRxiv.

[168]  A. Hill,et al.  ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice , 2017, Vaccine.

[169]  Ping Chen,et al.  Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission , 2020, Science China Life Sciences.

[170]  F. Pei,et al.  Severe Acute Respiratory Syndrome Associated Coronavirus Is Detected in Intestinal Tissues of Fatal Cases , 2005, The American Journal of Gastroenterology.

[171]  Z. Memish,et al.  Reducing mortality from 2019-nCoV: host-directed therapies should be an option , 2020, The Lancet.

[172]  R. Baric,et al.  Middle East Respiratory Syndrome Coronavirus NS4b Protein Inhibits Host RNase L Activation , 2016, mBio.

[173]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.